Seres Therapeutics (MCRB) Stock Forecast, Price & News

Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

Is Seres Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seres Therapeutics stock.
View analyst ratings for Seres Therapeutics or view top-rated stocks.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Seres Therapeutics.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) issued its quarterly earnings data on Wednesday, May, 4th. The biotechnology company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.05. Seres Therapeutics had a negative trailing twelve-month return on equity of 70.91% and a negative net margin of 61.65%. During the same period in the previous year, the company earned ($0.39) earnings per share.
View Seres Therapeutics' earnings history.

What price target have analysts set for MCRB?

5 Wall Street analysts have issued 12-month target prices for Seres Therapeutics' stock. Their forecasts range from $7.00 to $25.00. On average, they anticipate Seres Therapeutics' share price to reach $14.20 in the next twelve months. This suggests a possible upside of 343.8% from the stock's current price.
View analysts' price targets for Seres Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the following people:

• Mr. Eric D. Shaff M.B.A., Pres, CEO & Director (Age 46, Pay $1.09M)
• Dr. David S. Ege Ph.D., Exec. VP & Chief Technology Officer (Age 48, Pay $142.71k)
• Mr. Thomas J. DesRosier Esq., J.D., Chief Legal Officer, Exec. VP & Sec. (Age 67, Pay $719.55k)
• Mr. David A. Arkowitz M.B.A., Exec. VP, CFO & Head of Bus. Devel. (Age 61)
• Mr. Marcus Chapman, Sr. VP of Corp. Operations (Age 50)
• Dr. Matthew R. Henn Ph.D., Exec. VP & Chief Scientific Officer (Age 47)
• Mr. Carlo Tanzi Ph.D., Investor Relations Officer
• Ms. Kristin Ainsworth, Sr. VP of Corp. Communications
• Mr. Jeff York, VP of HR
• Ms. Paula A. Cloghessy SHRM-SCP, SPHR, Exec. VP & Chief People Officer (Age 50)

Who are some of Seres Therapeutics' key competitors?

Some companies that are related to Seres Therapeutics include Madrigal Pharmaceuticals (MDGL), Zentalis Pharmaceuticals (ZNTL), MannKind (MNKD), Agios Pharmaceuticals (AGIO), NGM Biopharmaceuticals (NGM), Cassava Sciences (SAVA), Reata Pharmaceuticals (RETA), Innoviva (INVA), Arcutis Biotherapeutics (ARQT), Vectura Group (VEGPF), Lyell Immunopharma (LYEL), Prometheus Biosciences (RXDX), BridgeBio Pharma (BBIO), Amneal Pharmaceuticals (AMRX) and Amneal Pharmaceuticals (AMRX).
View all of MCRB's competitors.

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), NVIDIA (NVDA), Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (8.69%), BlackRock Inc. (6.39%), Vanguard Group Inc. (5.49%), State Street Corp (5.26%), Nikko Asset Management Americas Inc. (0.79%) and Sumitomo Mitsui Trust Holdings Inc. (0.79%).
View institutional ownership trends for Seres Therapeutics.

Which institutional investors are selling Seres Therapeutics stock?

MCRB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Citigroup Inc., BNP Paribas Arbitrage SA, Qube Research & Technologies Ltd, PDT Partners LLC, Simplex Trading LLC, Group One Trading L.P., and Engineers Gate Manager LP.
View insider buying and selling activity for Seres Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Seres Therapeutics stock?

MCRB stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Dimensional Fund Advisors LP, Vanguard Group Inc., JPMorgan Chase & Co., UBS Group AG, State Street Corp, Goldman Sachs Group Inc., and BlackRock Inc..
View insider buying and selling activity for Seres Therapeutics or or view top insider-buying stocks.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $3.20.

How much money does Seres Therapeutics make?

Seres Therapeutics has a market capitalization of $295.14 million and generates $144.93 million in revenue each year. The biotechnology company earns $-65.58 million in net income (profit) each year or ($0.970010) on an earnings per share basis.

How many employees does Seres Therapeutics have?

Seres Therapeutics employs 333 workers across the globe.

What is Seres Therapeutics' official website?

The official website for Seres Therapeutics is www.serestherapeutics.com.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 945-9626 or via email at [email protected].